Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial

The Lancet
Jun 29, 2019 Volume 393Number 10191p2563-2654, e45
https://www.thelancet.com/journals/lancet/issue/current

 

Articles
Immunogenicity of full and fractional dose of inactivated poliovirus vaccine for use in routine immunisation and outbreak response: an open-label, randomised controlled trial
Cynthia J Snider, Khalequ Zaman, Concepcion F Estivariz, Mohammad Yunus, William C Weldon, Kathleen A Wannemuehler, M Steven Oberste, Mark A Pallansch, Steven GF Wassilak,
Tajul Islam A Bari, Abhijeet Anand
Background
Intradermal administration of fractional inactivated poliovirus vaccine (fIPV) is a dose-sparing alternative to the intramuscular full dose. We aimed to compare the immunogenicity of two fIPV doses versus one IPV dose for routine immunisation, and also assessed the immunogenicity of an fIPV booster dose for an outbreak response.
Interpretation
fIPV appears to be an effective dose-sparing strategy for routine immunisation and outbreak responses.